Trial NCT04649151
Publication Ali K, N Engl J Med, 2021
Primary outcome on the report: 1. Safety; 2. Reactogenicity; 3. Geometric mean titer ratio of pseudovirus neutralizing antibody titers; 4. Serologic response

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.